Impel Pharmaceuticals Announces Exploration of Strategic Alternatives
October 05, 2023 08:00 ET
|
Impel Pharmaceuticals
SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL) (“Impel” or “the Company”), a commercial-stage biopharmaceutical company with a mission to develop transformative...
Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
May 12, 2023 08:00 ET
|
Impel Pharmaceuticals
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor...
Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer
May 10, 2023 08:00 ET
|
Impel Pharmaceuticals
SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering...
Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 24, 2023 08:17 ET
|
Impel Pharmaceuticals
Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel to...
Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023
March 17, 2023 08:00 ET
|
Impel Pharmaceuticals
SEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from...
Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March
March 03, 2023 16:01 ET
|
Impel Pharmaceuticals
SEATTLE, March 03, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from...
Impel NeuroPharma to Participate in Upcoming Virtual Investor Conferences
February 28, 2022 08:00 ET
|
Impel NeuroPharma
SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with...
Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights
January 18, 2022 08:05 ET
|
Impel NeuroPharma
Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company’s Guidance Range Achieved Broad and Favorable...
Impel NeuroPharma to Present at the Guggenheim Securities 3rd Annual Neuro/Immunology Conference
November 09, 2021 08:00 ET
|
Impel NeuroPharma
SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases...
Impel NeuroPharma to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021
November 08, 2021 08:00 ET
|
Impel NeuroPharma
SEATTLE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases...